Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Canada's Apotex filed for approval of a Neulasta biosimilar in December and has also filed for approval of a Neupogen biosimilar that could be on the US market before the end of the year.

Since 2006, the European Union has approved 23 biosimilars, 16 of which are used in cancer; examples of recent approvals are CT-P10 and L01XC02, which are biosimilars of rituximab. 26 Worldwide, more ...

Troyen A. Brennan, Harvard University. Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However ...